Rapid Discovery of a Novel Series of Abl Kinase Inhibitors by Application of an Integrated Microfluidic Synthesis and Screening Platform

TLDR

Drug discovery must deliver lead molecules rapidly and efficiently, yet traditional paradigms impose significant time delays that hinder iterative design. The study applies a flow technology platform that integrates SAR generation to discover novel Abl kinase inhibitors. The platform combines flow chemistry for rapid synthesis, automated purification, and bioassay with Random‑Forest regression and chemical space sampling to iteratively refine an activity model. In just 21 compounds, the automated process identified a novel template and hinge‑binding motif with pIC50 > 8 against Abl kinase, including clinically relevant mutants, demonstrating the platform’s potential to reduce time and cost in hit‑to‑lead and lead optimization.

Abstract

Drug discovery faces economic and scientific imperatives to deliver lead molecules rapidly and efficiently. Using traditional paradigms the molecular design, synthesis, and screening loops enforce a significant time delay leading to inefficient use of data in the iterative molecular design process. Here, we report the application of a flow technology platform integrating the key elements of structure–activity relationship (SAR) generation to the discovery of novel Abl kinase inhibitors. The platform utilizes flow chemistry for rapid in-line synthesis, automated purification, and analysis coupled with bioassay. The combination of activity prediction using Random-Forest regression with chemical space sampling algorithms allows the construction of an activity model that refines itself after every iteration of synthesis and biological result. Within just 21 compounds, the automated process identified a novel template and hinge binding motif with pIC50 > 8 against Abl kinase — both wild type and clinically relevant mutants. Integrated microfluidic synthesis and screening coupled with machine learning design have the potential to greatly reduce the time and cost of drug discovery within the hit-to-lead and lead optimization phases.